These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 18572247)
21. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
22. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816 [TBL] [Abstract][Full Text] [Related]
23. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468 [TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
26. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O; J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437 [TBL] [Abstract][Full Text] [Related]
27. [Highly active antiretroviral therapy in HIV sero-positive children. Disease progression by baseline clinical, immunological and virological status]. Rodríguez de Schiavi MS; Scrigni A; García Arrigoni P; Bologna R; Barboni G; Redondo J; Nastri M; Mecikovsky D; Cantisano C; Moreno R; Siciliani D; Lencina M; Luedicke N; Rezzónico G; Torolla JL; López Papucci S; Luis M; Libonati C; Gamba L; Barbarysky J; Pérez Hernández E; Zlatkes R Arch Argent Pediatr; 2009 Jun; 107(3):212-20. PubMed ID: 19543629 [TBL] [Abstract][Full Text] [Related]
28. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome. Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761 [TBL] [Abstract][Full Text] [Related]
29. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. Maggiolo F; Airoldi M; Callegaro A; Martinelli C; Dolara A; Bini T; Gregis G; Quinzan G; Ripamonti D; Ravasio V; Suter F AIDS; 2009 Apr; 23(7):799-807. PubMed ID: 19114869 [TBL] [Abstract][Full Text] [Related]
30. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135 [TBL] [Abstract][Full Text] [Related]
31. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. Seminari E; De Silvestri A; Boschi A; Tinelli C AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979 [TBL] [Abstract][Full Text] [Related]
33. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Van der Borght SF; Clevenbergh P; Rijckborst H; Nsalou P; Onyia N; Lange JM; de Wit TF; Van der Loeff MF Antivir Ther; 2009; 14(1):63-74. PubMed ID: 19320238 [TBL] [Abstract][Full Text] [Related]
34. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Lohse N; Hansen AB; Jensen-Fangel S; Kronborg G; Kvinesdal B; Pedersen C; Larsen CS; Møller A; Willumsen L; Obel N Scand J Infect Dis; 2005; 37(5):338-43. PubMed ID: 16051569 [TBL] [Abstract][Full Text] [Related]
35. Subclinical hypothyroidism in HIV-infected subjects. Bongiovanni M; Adorni F; Casana M; Tordato F; Tincati C; Cicconi P; Bini T; d'Arminio Monforte A J Antimicrob Chemother; 2006 Nov; 58(5):1086-9. PubMed ID: 16950823 [TBL] [Abstract][Full Text] [Related]
36. Loss to follow-up in an international, multicentre observational study. Mocroft A; Kirk O; Aldins P; Chies A; Blaxhult A; Chentsova N; Vetter N; Dabis F; Gatell J; Lundgren JD; HIV Med; 2008 May; 9(5):261-9. PubMed ID: 18400074 [TBL] [Abstract][Full Text] [Related]
37. The three-year positivity rate of sexually transmitted infections among a group of HIV-infected men attending the Department of Genitourinary Medicine, Edinburgh, UK. Manavi K; Luo PL; McMillan A Int J STD AIDS; 2005 Nov; 16(11):730-2. PubMed ID: 16303066 [TBL] [Abstract][Full Text] [Related]
38. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS. Josephs JS; Fleishman JA; Gaist P; Gebo KA; HIV Med; 2007 Jul; 8(5):300-5. PubMed ID: 17561876 [TBL] [Abstract][Full Text] [Related]
39. Changes in HIV-related hospitalizations during the HAART era in an inner-city hospital. Pulvirenti J; Muppidi U; Glowacki R; Cristofano M; Baker L AIDS Read; 2007 Aug; 17(8):390-4, 397-401. PubMed ID: 17717882 [TBL] [Abstract][Full Text] [Related]